Active Biotech publishes pre-clinical data regarding the TASQ prostate cancer project

The i-Technology Media!	Register \| Log in

.NET · AJAX · CLOUD · ECLIPSE · FLEX · OPEN WEB · iPHONE · JAVA · LINUX · OPEN SOURCE · ORACLE · PBDJ · SEARCH · SILVERLIGHT · SOA · VIRTUALIZATION · WEB 2.0 · WIRELESS · XML

Comments

Drool, Britannia? Is the UK Failing the Cloud?

By Roger Strukhoff

Richard Davies wrote: The UK has a good crop of technology pioneers in cloud computing - for example ElasticHosts, FlexiScale, Flexiant, OnApp - and also some strong government initiatives such as G-Cloud. We will have to see whether this kind of technical leadership converts into swift mass-market adoption or not.

Jan. 8, 2012 11:38 AM EST

read more & respond »

Cloud Expo on Google News

Did you read today's front page stories & breaking news?

Cloud Expo & Virtualization 2011 West

Keynotes

Oracle

Opening Keynote | An Enterprise Cloud for Business-Critical Applications

Abiquo

Day 2 Keynote | The Enterprise Cloud Tightrope - Balancing for Success

Akamai

Day 3 Keynote | The DNA of an Enterprise Cloud

DIAMOND SPONSOR:

Oracle

Many Clouds, Many Choices'Cloud

PLATINUM PLUS SPONSORS:

Abiquo

Enterprise Cloud Best Practices - Town Hall - Join the discussion…

PLATINUM SPONSORS:

Intel

Progressing Toward the Federated, Automated and Client-Aware Cloud

New Relic

How to build an app with Twitter-like throughput

Rackspace

Computing in the Cloud Era

GOLD SPONSORS:

Gale Technologies

Practical Cloud Migration

IBM

Re-think IT. Re-inventing Business.

Intel/McAfee

Identity Driven Security in the Cloud

PerspecSys

Hackers Hackers Everywhere, Is My Public Cloud That Safe?

Red Hat

Unlock the Value of the Cloud

SHI

Mission Critical Applications and the Cloud - Myth or Reality?

SoftLayer

Not Your Grandpa's Cloud

Terremark

Integrating Enterprise Clouds

VMware

Upgrade to a vCloud

POWER PANELS:

Cloud Expo Silicon Valley: CTO Power Panel

Cloud Expo Silicon Valley: CEO Power Panel

Cloud Expo Silicon Valley: Cloud SuperStars Panel

Cloud Expo Silicon Valley: CloudNOW Panel

Click For 2010 West
Event Webcasts

Cloud Expo & Virtualization 2011 East

DIAMOND SPONSOR:

Dell

Dell & VMware Deliver the Enterprise Hybrid Cloud

PLATINUM PLUS SPONSORS:

Abiquo

Are Financial Services Organizations Risking Security by Avoiding Cloud Computing?

Oracle

From Consolidation to Enterprise Private PaaS

PLATINUM SPONSORS:

Intel

Driving the Transformation to Next Generation Cloud Data Centers

Rackspace

The Inevitability of an Open Cloud

GOLD SPONSORS:

CA Technologies

Follow YOUR path to Cloud Computing

Interxion

Who Keeps the Cloud in the Air?

Microsoft

Patterns for Cloud Computing

PerspecSys

War in the Clouds: Are you ready?

ServiceMesh

The Big Win: Stop Playing Small-Ball with Your Cloud Strategy

Terremark

Evaluating Enterprise Clouds

Xiotech

Cloud Storage: Myths and Realities

POWER PANELS:

Cloud Expo New York: CTO Power Panel

Cloud Expo New York: CEO Power Panel

Cloud Expo New York: CMO Power Panel

Cloud Expo New York: Wrap-Up Power Panel

Click For 2010 West
Event Webcasts

Live Google News by SYS-CON!

Top Three Links You Must Click On

From the Wires

Active Biotech publishes pre-clinical data regarding the TASQ prostate cancer project

By: Marketwire .

Sep. 7, 2006 02:22 PM

LUND, SWEDEN -- (MARKET WIRE) -- 09/07/06 -- Active Biotech (ACTI.ST) publishes a new scientific paper - "Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer" - in the next issue of the scientific journal "Prostate" (pre-available as an e-publication at NCBI National Center for Biotechnology, http://www.ncbi.nlm.nih.gov/) in collaboration with Professor John T. Isaacs of Johns Hopkins University in Baltimore, USA.

The article summarizes pre-clinical data regarding Active Biotech's project TASQ for the treatment of prostate cancer.

The data verifies TASQ's anti-angiogenic activity i.e. inhibition of the growth of new blood vessels into the tumor, and is paralleled by an inhibition of tumor growth.

The objective for the company's TASQ project is to develop a pharmaceutical product that can be administered orally for the chronic treatment of prostate cancer.

Currently TASQ is in Phase I clinical trials in prostate cancer patients.

An interim evaluation of this study will be communicated separately within short.

Phase II/III studies are scheduled to commence in 2007.

Lund, September 7, 2006
Active Biotech AB (publ)

Sven Andréasson
President & CEO

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.

Active Biotech AB
Box 724, SE-220 07 Lund
Tel: +46 46-19 20 00
Fax: +46 46-19 20 50
www.activebiotech.com

About Marketwire .
Copyright © 2009 Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.